Findings: Don’t blame patients for all inhaler-use errors; singing may help improve breathing, QOL; Rx adherence does improve over time; plus 3 more outcomes of interest.
IPF Update: FIBRONEER-IPF Study of Nerandomilast Meets Primary End Point
The positive pivotal phase 3 trial results showed improved lung function with neradomilast vs placebo and will support BI's US and global NDA submissions.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Roflumilast Associated with Increase in 5-Year Mortality Risk in Patients with COPD
In a large study of patients with COPD, a small increase in 5-year all-cause mortality risk was observed among those using roflumilast.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
Long Colds: How to Manage Patient Expectation About Duration of the Common Cold
Patients largely underestimate how long a cold should last and the lingering symptoms too often prompt a request for antibiotics. Primary care, please resist!
ME/CFS Rates No Different After COVID-19 Infection than After Other Acute Infection-Like Illnesses
The rate of ME/CFS was similar (3% to 4%) at 3 through 12 months for study participants who tested positive and negative for COVID-19.